ClinicalTrials.gg

Program

brexpiprazole

Also written as “Brexpiprazole”, “OPC-34712” and “Brexpiprazole (OPC-34712)”.

Its studies are mostly in Schizophrenia · Depressive Disorder, Major · Stress Disorders, Post-Traumatic · Alzheimer Disease · Mania, led by 3 companies.

Furthest: phase 4, since Mar 29, 202170 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsuka600 open or runningphase 4since Mar 29, 2021Nov 24, 2008none ahead
H. Lundbeck90 open or runningphase 3since Mar 11, 2013Mar 11, 2013none ahead
Humanis Saglık Anonim Sirketi10 open or runningphase 1since Dec 4, 2025Dec 4, 2025none ahead

Also a collaborator on its studies: quintiles-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 42 studies since Jul 11, 2011.

  1. May 7, 2018Phase 3 study in Alzheimer DiseaseOtsuka · NCT03548584 · 345 enrolled · United States
  2. Jul 11, 20183 phase 3 studiesOtsuka · NCT03594123, NCT03697603, NCT03737474
  3. Aug 5, 2018Phase 3 study in Agitation Associated With Dementia of the Alzheimer's TypeOtsuka · NCT03620981 · 410 enrolled · Japan
  4. Oct 28, 2018Phase 3 study in Agitation Associated With Dementia of the Alzheimer's TypeOtsuka · NCT03724942 · 164 enrolled · Japan
  5. Nov 2, 20182 phase 1 studiesOtsuka · NCT03734354, NCT03734302
  6. Mar 12, 2019Phase 3 study in SchizophreniaOtsuka · NCT03874494 · 371 enrolled · China
  7. Sep 20, 2019Phase 2 study in Borderline Personality DisorderOtsuka · NCT04100096 · 332 enrolled · United States, Spain, Ukraine
  8. Oct 10, 2019Phase 3 study in Stress Disorders, Post-TraumaticOtsuka · NCT04124614 · 450 enrolled · United States
  9. Nov 20, 20192 phase 3 studiesOtsuka · NCT04174365, NCT04174170
  10. Dec 2, 2019Phase 3 study in Borderline Personality DisorderOtsuka · NCT04186403 · 201 enrolled · United States
  11. Feb 4, 2020Phase 3 study in Autistic DisorderOtsuka · NCT04258839 · 95 enrolled · United States
  12. Mar 29, 2021Phase 4 study in Depressive Disorder, MajorOtsuka · NCT04830215 · 122 enrolled · Canada
  13. May 31, 2022Phase 4 study in Depressive Disorder, MajorOtsuka · NCT05504486
  14. Dec 4, 2025Humanis Saglık Anonim Sirketi's first study: phase 1 study in SchizophreniaNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT07266792 · 36 enrolled · India

TargetBeta

“Dopamine D2 receptor partial agonist; Serotonin 1a (5-HT1a) receptor partial agonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
AripiprazoleruleOtsukaphase 4131

Studies

The newest 60 of 70 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07266792Schizophrenia · India1CompletedHumanis Saglık Anonim SirketiAug 4, 202536
NCT05504486Depressive Disorder, Major4WithdrawnOtsukaMar 22, 20230
NCT04830215Depressive Disorder, Major · Canada4CompletedOtsukaMay 27, 2022122
NCT04258839Autistic Disorder · United States3CompletedOtsukaMar 16, 202395
NCT04186403Borderline Personality Disorder · United States3CompletedOtsukaSep 22, 2021201
NCT04174170Stress Disorders, Post-Traumatic · United States3CompletedOtsukaJul 25, 2023591
NCT04174365Autistic Disorder · United States3CompletedOtsukaAug 8, 2022119
NCT04124614Stress Disorders, Post-Traumatic · United States3CompletedOtsukaJul 19, 2023450
NCT04100096Borderline Personality Disorder · United States, Spain, Ukraine2CompletedOtsukaJun 27, 2021332
NCT03874494Schizophrenia · China3CompletedOtsukaAug 6, 2021371
NCT03734354Health · China1CompletedOtsukaMay 18, 202030
NCT03734302Healthy · China1CompletedOtsukaJun 10, 202010
NCT03724942Agitation Associated With Dementia of the Alzheimer's Type · Japan3CompletedOtsukaDec 2, 2021164
NCT03620981Agitation Associated With Dementia of the Alzheimer's Type · Japan3CompletedOtsukaApr 21, 2023410
NCT03737474Depressive Disorder, Major · Japan3CompletedOtsukaMar 17, 2021248
NCT03697603Depressive Disorder, Major · Japan3CompletedOtsukaJun 6, 2022740
NCT03594123Alzheimer Disease · United States3CompletedOtsukaSep 19, 2022259
NCT03548584Alzheimer Disease · United States3CompletedOtsukaMay 23, 2022345
NCT03538691Depressive Disorder, Major · United States3CompletedOtsukaJul 8, 20221,149
NCT03487198Depressive Disorder, Major · China3TerminatedOtsukaMay 30, 201965
NCT03292848Attention Deficit Disorder with Hyperactivity · United States1CompletedOtsukaMay 21, 201824
NCT03287869Mania · United States, Bulgaria, Croatia and more3CompletedOtsukaJul 31, 2019381
NCT03259555Mania · United States, Bulgaria, Poland and more3CompletedOtsukaJan 2, 2019322
NCT03257865Mania · United States, Croatia, Ukraine3CompletedOtsukaJan 22, 2019333
NCT03238326Schizophrenia · United States, France, Italy and more3CompletedOtsukaApr 22, 2025295
NCT03198078Schizophrenia · United States3CompletedOtsukaApr 3, 2023316
NCT03033069Stress Disorders, Post-Traumatic · United States2CompletedOtsukaNov 12, 2018336
NCT02968121Schizophrenia · United States1TerminatedOtsukaDec 14, 201722
NCT02875080Healthy Adult Male · Japan1CompletedOtsukaNov 27, 201618
NCT02758067Schizophrenia3WithdrawnH. LundbeckJun 20160
NCT02212613Depressive Disorder, Major · United States3WithdrawnOtsukaNov 20150
NCT02196506Depressive Disorder · United States, Germany, Hungary and more3CompletedOtsukaApr 2016837
NCT02194933Schizophrenia · United States3CompletedOtsukaApr 201638
NCT02411695Schizophrenia · United States1CompletedOtsukaJan 1, 201743
NCT02054702Schizophrenia3CompletedOtsukaJun 201497
NCT02013622Schizophrenia · United States3CompletedOtsukaSep 201449
NCT02013609Schizophrenia · United States3CompletedOtsukaSep 201448
NCT02013531Depressive Disorder, Major · United States3CompletedOtsukaMay 201437
NCT02012218Depressive Disorder, Major · United States3CompletedOtsukaOct 201461
NCT01987960Stress Disorders, Post-Traumatic · United States, Estonia, Finland and more3TerminatedH. LundbeckOct 2015417
NCT01944969Depressive Disorder, Major · United States3TerminatedH. LundbeckMay 201426
NCT01942785Depressive Disorder, Major · United States3CompletedH. LundbeckJul 201455
NCT01942733Parasomnias3CompletedH. LundbeckAug 201444
NCT01922258Alzheimer Disease · United States, Bulgaria, Canada and more3CompletedOtsukaMar 2017270
NCT01862640Alzheimer Disease · United States, Croatia, Germany and more3CompletedOtsukaMar 15, 2017433
NCT01854944Schizophrenia · United States1CompletedOtsukaJul 201412
NCT01838681Depressive Disorder, Major · United States, Bulgaria, Canada and more3CompletedH. LundbeckJun 20161,986
NCT01837797Depressive Disorder, Major · United States3TerminatedH. LundbeckMay 2014129
NCT01810783Schizophrenia · United States, Estonia, Poland and more3CompletedH. LundbeckDec 2015210
NCT01810380Schizophrenia · United States3CompletedH. LundbeckDec 2014468
NCT01727726Depressive Disorder · United States, Canada, France and more3CompletedOtsukaOct 17, 20162,182
NCT01668797Acute Schizophrenia · United States, Colombia, Malaysia and more3CompletedOtsukaJan 2015524
NCT01670279Depressive Disorder, Major · United States1CompletedOtsukaMay 201318
NCT01649557Schizophrenia · United States, Bulgaria, Croatia and more2CompletedOtsukaAug 2011244
NCT01456897Schizophrenia · Japan3CompletedOtsukaMay 2015282
NCT01451164Schizophrenia · Japan3CompletedOtsukaJun 2015459
NCT01447576Depressive Disorder, Major · United States2CompletedOtsukaDec 20121,036
NCT01423916Schizophrenia · United States1CompletedOtsukaFeb 2012218
NCT01397786Schizophrenia · United States, Canada, Colombia and more3CompletedOtsukaJan 20161,044
NCT01396421Acute Schizophrenia · United States, Canada, Japan and more3CompletedOtsukaJan 2014636

How it is read

Names in the registry

  • “Brexpiprazole”, 44 entries
  • “OPC-34712”, 17 entries
  • “Brexpiprazole (OPC-34712)”, 2 entries
  • “Brexpiprazole, OPC-34712”, 2 entries
  • “OPC-34712 + ADT”, 2 entries

Codes read as this program: OPDC34712.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.